title: The additionally glycosylated variant of human sex hormone-binding globulin (SHBG) is linked to estrogen-dependence of breast cancer.
abstract: Sex Hormone-Binding Globulin (SHBG), the plasma carrier for androgens and estradiol, inhibits the estradiol-induced proliferation of breast cancer cells through its membrane receptor, cAMP, and PKA. In addition, the SHBG membrane receptor is preferentially expressed in estrogen-dependent (ER+/PR+) breast cancers which are also characterized by a lower proliferative rate than tumors negative for the SHBG receptor. A variant SHBG with a point mutation in exon 8, causing an aminoacid substitution (Asp 327-->Asn) and thus, the introduction of an additional N-glycosylation site, has been reported. In this work, the distribution of the SHBG variant was studied in 255 breast cancer patients, 32 benign mammary disease patients, and 120 healthy women. The presence of the SHBG mutation was evaluated with PCR amplification of SHBG exon 8 and Hinf I restriction fragment length polymorphism (RFLP) procedure. This technique allowed us to identify 54 SHBG variants (53 W/v and 1 v/v) in breast cancer patients (21.2%), 5 variants (4 W/v and 1 v/v) in benign mammary disease patients (15.6%), and 14 variants (W/v) in the control group (11.6%). The results of PCR and RFLP were confirmed both by nucleotide sequence of SHBG exon 8 and western blot of the plasma SHBG. No differences in the mean plasma level of the protein were observed in the three populations. The frequency of the SHBG variant was significantly higher in ER+/PR+ tumors and in tumors diagnosed in patients over 50 years of age than in the control group. This observation suggests the existence of a close link between the estrogen-dependence of breast cancer and the additionally glycosylated SHBG, further supporting a critical role of the protein in the neoplasm.
authors.affiliation: Laboratorio di Endocrinologia, Dip. Fisiopatologia Clinica & II UOADU Medicina Generale, Azienda Ospedaliera S. Giovanni Battista, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Becchis
authors.forename: R
authors.initials: R
authors.lastname: Frairia
authors.forename: P
authors.initials: P
authors.lastname: Ferrera
authors.forename: A
authors.initials: A
authors.lastname: Fazzari
authors.forename: S
authors.initials: S
authors.lastname: Ondei
authors.forename: A
authors.initials: A
authors.lastname: Alfarano
authors.forename: C
authors.initials: C
authors.lastname: Coluccia
authors.forename: N
authors.initials: N
authors.lastname: Biglia
authors.forename: P
authors.initials: P
authors.lastname: Sismondi
authors.forename: N
authors.initials: N
authors.lastname: Fortunati
mesh_terms: D019943:Amino Acid Substitution; D001120:Arginine; D001216:Asparagine; D001483:Base Sequence; D001940:Breast / Q000166:cytology; D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology*; D002455:Cell Division / Q000187:drug effects; D004958:Estradiol / Q000494:pharmacology*; D005091:Exons; D005260:Female; D005348:Fibrocystic Breast Disease / Q000235:genetics / Q000473:pathology; D014644:Genetic Variation; D006031:Glycosylation; D006801:Humans; D017354:Point Mutation; D012150:Polymorphism, Restriction Fragment Length; D012016:Reference Values; D012738:Sex Hormone-Binding Globulin / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism
chemical_list: D012738:Sex Hormone-Binding Globulin; D004958:Estradiol; D001216:Asparagine; D001120:Arginine